Monday, March 21 2016 18:45

Forbes describes activities of Noubar Afeyan, American businessman of Armenian descent

Forbes describes activities of Noubar Afeyan, American businessman of Armenian descent

ArmInfo. "Starting one successful company is a fine achievement.  How does one describe someone who has helped found 38 companies?" Forbes says, presenting the biography of Noubar Afeyan, American businessman of Armenian descent. 

Noubar Afeyan was born to Armenian parents in Lebanon. At the age of 13, he immigrated with his family to Canada and attended college there. Noubar was accepted to a Ph.D. program at the Massachusetts Institute of Technology (MIT), at the time the only school with an advanced program in biochemical engineering. After earning his Ph.D. at the age of 24, Noubar started his first company.  For 10 years, Noubar Afeyan headed PerSeptive Biosystems, which became the number two company in the bio- instrumentation field before it was acquired by Perkin Elmer/Applera Corporation in 1998.  While CEO of PerSeptive Biosystems he founded or co-founded 5 more companies.

Recent research from the National Foundation for American Policy (NFAP) reported on the strong entrepreneurial drive of many immigrants, examining the impact of immigrants on the current universe of "billion dollar" startups. The impact is significant. "Immigrants have started more than half (44 of 87) of America's startup companies valued at $1 billion or more and are key members of management or product development teams in over 70 percent (62 of 87) of these companies," according to the NFAP study. These billion dollar startups with at least one immigrant founder have created an average of more than 700 jobs per company.

In 1999, Noubar evaluated the way his startups were formed - and startups in general - and thought perhaps the often disjointed, "trial and error" approach typical of startups could be reduced to something more systematic and organized. That's when he founded Flagship Ventures, which develops new companies through its in-house division VentureLabs. It also invests in startups.

VentureLabs, which Noubar oversees as senior managing partner and CEO of Flagship Ventures, takes a unique approach. It conducts its own research and forms new companies after the research has started to bear fruit. Using this approach, Flagship Ventures and VentureLabs have launched dozens of startup companies, primarily in the life sciences and sustainability.

"We spend a lot of time at Flagship Ventures identifying problems and coming up with solutions that produce intellectual property that can be used to create innovations and ultimately new approaches and new companies," Forbes quotes Afeyan as saying. Noubar has over 100 patents to his name.

Moderna Therapeutics, which Noubar co-founded and helps lead as chairman, may be Flagship Ventures' most successful startup. Founded in 2009, the Cambridge, Massachusetts-based company is already valued at $3 billion and employs over 300 people.


News


Exchange rates
27.01.2021
RUB6.890.03
USD518.16-0.10
EUR628.06-0.43
GBP711.593.80
CAD407.130.59
JPY49.92-0.02
CNY80.130.21
CHF583.190.35



Government Bonds

Issue volume

10 billion

Volume of T-bills for placement

200 million

Volume of submitted competitive applications

200 million

Volume of satisfied bids

200 million

Yield at cut-off price

 5.8314%

Maximum yield

 5.8314%

Мinimum yield

 5.8314%

Weighted average yield

 5.8314%

Number of participants

2

The maturity date of T-bills

03.02.2020

ArmEx

 

СПРОС (Покупка)

USD

Средневзв. Цена

482,00

ПРЕДЛОЖЕНИЕ (Продажа)

  USD

Средневзв. Цена

-

СДЕЛКИ

USD

Цена откр.

482,00

Цена закр.

482,00

Мин. Цена

482,00

Макс. Цена

482,00

Ср/взв. Цена

482,00

-0.16

Кол-во сделок

1

Объем (инвал.)

200 000

0бъем (драм)

96 400 000